CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Norris Medicines Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Norris Medicines Ltd
Plot No. 801/P
901/3-5 GIDC Industrial Estate
Phone: +91 2646223462p:+91 2646223462 ANKLESHWAR, 393002  India Ticker: 524414524414
Business Summary
Norris Medicines Limited is an India-based company, which is focused on the health care industry. It also focused on manufacturing of injections and medicinal formulations. It is engaged in carrying out contract manufacturing and loan license manufacturing for large multinational and big Indian pharma companies. It offers Antibiotic Range, Antiinflammatory / Pain Management, Anti-Emetic, Nutrition, Cough/Cold, Skin & Allergy, Anti-Malaria and other products. Its Antibiotic product range includes Arizon-100, Arizon-250, Arizon-500, Cefan-dry syurp, Cefan DT-50, Cefan DT-100, Cefan DT-200, and others. Its Anti-Emetic products include Onvin Syrup and Onvin. Nutrition products include Can-D XP, Cand Fort, Hemfit Plus Syrup, Hemfit-Z, and others. Its Anti-Malaria products include Antimal DT-20, Antimal DT-80, Antimal Dry Syrup and Antimal. Its Diabeticals Cardiac products include Amlonor-5, Amlonor-A, Atvinor-10, Enorpril-2.5, Enorpril-5, Lostinor-25, Raminor-5, Glynor-MF and others.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20243/31/2024Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Financial Officer IqubalPatel
Managing Director, Executive Director Vimal D.Shah 47 1/1/2024 2/20/2012
Company Secretary PriyankaLohiya 7/3/2024 7/3/2024
Non-Executive Director Praveen J.Bafna 58 8/24/2024 8/24/2024
Non-Executive Independent Director AngamuthuVadivel 51 4/29/2024 4/29/2024

General Information
Outstanding Shares: 10,000,700 (As of 9/30/2024)
Stock Exchange: BOM
Fax Number: +91 2646250126


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, November 21, 2024